ARROWHEAD PHARMACEUTICALS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ARWR in the last 30 days.
See all $ARWR insider activity →The MHRA authorized Arrowhead Pharmaceuticals' plozasiran (Redemplo) to reduce triglycerides in adults with familial chylomicronaemia syndrome (FCS). A phase 3 trial showed an 80% median reduction in triglycerides with plozasiran vs. 17% with placebo. The drug is administered as a 25-mg subcutaneous injection every 3 months. Common side effects include hyperglycemia, headache, and nausea.
The FDA launched a Rare Disease Framework Initiative to boost drug development for rare diseases. Arrowhead Pharmaceuticals reported a 73% decrease in tau protein in a Phase 1/2a study of ARO-MAPT. First Tracks Biotherapeutics announced positive Phase 1b results for ANB033 in celiac disease. BioNTech's BNT113 missed its first primary endpoint in a head and neck cancer trial. GSK plans to cut over 1,000 jobs at a Belgium site.
UBS raised its price target for Arrowhead Pharmaceuticals to $109 from $63, maintaining a buy rating. The stock is currently trading at $59.04, up 1.16% on the day but down 3.18% over the past year. The adjustment reflects positive sentiment on the company's prospects.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ARWR (ARROWHEAD PHARMACEUTICALS, INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent ARWR coverage spans financial news, technology and regulation.
Regulatory approval in the UK opens market for Arrowhead's drug, likely boosting share price.
Positive early data may boost investor optimism and drive short-term buying pressure.
Analyst target increase suggests upside potential for the stock.
Positive early‑stage data may boost investor confidence in Arrowhead's BBB platform versus Biogen's antisense approach.
Positive trial data and higher price target likely drive the stock higher.
AlphAI scores every news story that mentions ARWR with an AI model for sentiment and relevance, and aggregates insider trades from ARROWHEAD PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
The MHRA authorized Arrowhead Pharmaceuticals' plozasiran (Redemplo) to reduce triglycerides in adults with familial chylomicronaemia syndrome (FCS). A phase 3 trial showed an 80% median reduction in triglycerides with plozasiran vs. 17% with placebo. The drug is administered as a 25-mg subcutaneous injection every 3 months. Common side effects include hyperglycemia, headache, and nausea.
2 min readThe FDA launched a Rare Disease Framework Initiative to boost drug development for rare diseases. Arrowhead Pharmaceuticals reported a 73% decrease in tau protein in a Phase 1/2a study of ARO-MAPT. First Tracks Biotherapeutics announced positive Phase 1b results for ANB033 in celiac disease. BioNTech's BNT113 missed its first primary endpoint in a head and neck cancer trial. GSK plans to cut over 1,000 jobs at a Belgium site.
4 min readUBS raised its price target for Arrowhead Pharmaceuticals to $109 from $63, maintaining a buy rating. The stock is currently trading at $59.04, up 1.16% on the day but down 3.18% over the past year. The adjustment reflects positive sentiment on the company's prospects.
1 min readArrowhead Pharmaceuticals' ARO-MAPT showed significant tau protein reduction in a Phase 1/2a study, with up to 85% reduction at high doses. Analysts view the data favorably, suggesting a potential competitive edge over Biogen's diranersen. The trial is ongoing, with safety data showing the drug was well tolerated. Arrowhead plans further studies and potential expansion into other diseases.
3 min readChardan Capital reaffirmed its Buy rating on Arrowhead Pharma with a $115 price target, suggesting a 97% upside from the last close. The target is based on strong clinical data and growth potential from its RNAi therapies.
2 min readHC Wainwright & Co. maintained a Buy rating on Arrowhead Pharma with a $120 price target, suggesting a 105.6% upside from the Oct 14 close. The firm cited strong clinical data from a Phase 1/2a trial and strategic development plans for rare CNS diseases.
1 min readArrowhead's Alzheimer's drug reduced tau in a Phase I/IIa trial. J&J's posdinemab failed in Phase IIb. Eisai's etalanetug, Biogen's diranersen, TauRx's hydromethylthionine, and Annovis Bio's buntanetap are in development. The Alzheimer's market is projected to grow from $2.4bn to $14.7bn by 2033, with a CAGR of 20%.
2 min readArrowhead Pharmaceuticals reported interim Phase 1/2a data showing its drug ARO-MAPT reduced CSF total tau by up to 85% in healthy volunteers, with a mean reduction of 73% at Day 105. The drug was generally well tolerated. This is early-stage data for Arrowhead's CNS RNAi platform.
1 min readArrowhead Pharmaceuticals (ARWR) announced FDA's STAR pilot program entry for plozasiran, accelerating its review for severe hypertriglyceridemia. The program shortens review time to 6 months. ARWR plans to submit the application by year-end 2026. Plozasiran is already approved for a similar condition.
2 min readArrowhead Pharmaceuticals (ARWR) saw a 77.7% stock price increase over the past year, reaching $64.19. The company reported positive Phase 3 trial results for plozasiran, with revenue growing from $27.767m to $75.253m in Q3 2026, but net losses increased. Analysts' fair value estimates range from $17 to $46.15, depending on revenue growth and profit margin assumptions. The company's future outlook depends on the success of its RNAi pipeline and potential partnerships.
2 min read
